Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021
Research

Seroprevalence of SARS-CoV-2–Specific Antibodies among Quarantined Close Contacts of COVID-19 Patients, Faroe Islands, 2020

Maria Skaalum PetersenComments to Author , Marnar Fríðheim Kristiansen, Halla Weihe Reinert, Jógvan Páll Fjallsbak, Debes Hammershaimb Christiansen, Shahin Gaini, Bjarni á Steig, Lars Fodgaard Møller, Marin Strøm, and Pál Weihe
Author affiliations: University of the Faroe Islands, Tórshavn, Faroe Islands (M.S. Petersen, M.F. Kristiansen, S. Gaini, M. Strøm, P. Weihe); The Faroese Hospital System, Tórshavn (M.S. Petersen, H.W. Reinert, P. Weihe); National Hospital of the Faroe Islands, Tórshavn (M.F. Kristiansen, S. Gaini, B. á Steig); COVID-19 Task Force, Ministry of Health, Tórshavn (M.F. Kristiansen, B. á Steig); Faroese Food and Veterinary Authority, Tórshavn (J.P. Fjallsbak, D.H. Christiansen); Odense University Hospital, Odense, Denmark (S. Gaini); University of Southern Denmark, Odense (S. Gaini); Chief Medical Officer Office, Tórshavn (L.F. Møller); Statens Serum Institut, Copenhagen, Denmark (M. Strøm)

Main Article

Table 1

Demographic and clinical characteristics of 584 quarantined close contacts of coronavirus disease patients in study of seroprevalence of SARS-CoV-2–specific antibodies, Faroe Islands, 2020*

Characteristic Close contacts
p value†
Total Seronegative Seropositive
Total
584 (100.0)
552 (100.0)
32 (100.0)

Sex 0.8
F 339 (58.0) 321 (58.2) 18 (56.3)
M
245 (42.0)
231 (41.8)
14 (43.8)

Mean age, y (SD) [range]
36.5 (20.2) [0.2–83.8]
37.0 (19.9) [0.2–81.7]
28.1 (24.0) [1.4–83.8]
0.02
Age group, y <0.01
0–9 69 (11.8) 61 (11.1) 8 (25.0)
10–17 68 (11.6) 62 (11.2) 6 (18.8)
18–34 134 (22.9) 125 (22.6) 9 (28.1)
35–49 131 (22.4) 128 (23.2) 3 (9.4)
50–66 150 (25.7) 148 (26.8) 2 (6.3)
>67
32 (5.5)
28 (5.1)
4 (12.5)

Smoking status‡ 0.1
Active 93 (16.7) 92 (17.4) 1 (3.6)
Occasional 41 (7.3) 40 (7.5) 1 (3.6)
Former 127 (22.8) 121 (22.8) 6 (21.4)
Never
297 (53.2)
277 (52.3)
20 (71.4)

Daily medication use§ 0.6
Yes 145 (27.8) 137 (27.6) 8 (32.0)
No
376 (72.2)
359 (72.4)
17 (68.0)

Self-reported chronic diseases‡ 0.06
Yes 278 (49.8) 268 (50.6) 10 (35.7)
No
280 (50.2)
262 (49.4)
18 (64.3)

Had PCR during quarantine¶ 0.2
Yes 263 (48.3) 249 (47.8) 21 (65.6)
No
281 (51.7)
272 (52.2)
11 (34.4)

Had symptoms during quarantine# 0.7
Yes 116 (21.4) 112 (21.6) 14 (43.8)
No 345 (63.5) 327 (63.1) 18 (56.3)
Not sure
82 (15.1)
79 (15.3)
0

Had other family members in quarantine** 0.2
No 120 (21.8) 118 (22.5) 2 (7.4)
Yes, together 373 (67.7) 352 (67.2) 21 (77.8)
Yes, separated
58 (10.5)
54 (10.3)
4 (14.8)

Type of contact†† <0.01
Household 145 (28.9) 125 (26.5) 20 (64.5)
Workplace 184 (36.7) 179 (38.0) 5 (16.1)
Other 173 (34.5) 167 (35.5) 6 (19.4)

*Values are no. (%) except as indicated. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †p values determined by χ2 test for categorical variables or analysis of variance for continuous variables. ‡Questionnaire data missing for 26 quarantined close contacts, including 4 seropositive contacts. §Questionnaire data missing for 63 quarantined close contacts, including 7 seropositive contacts. ¶Questionnaire data missing for 40 quarantined close contacts, including 9 seropositive contacts. However, all seropositive patients were asked about PCR; as a result, values do not add up. #Questionnaire data missing for 41 quarantined close contacts, including 7 seropositive contacts. However, all seropositive patients were asked about symptoms; as a result, values do not add up. **Questionnaire data missing for 33 quarantined close contacts, including 5 seropositive contacts. ††Questionnaire data missing for 82 quarantined close contacts, including 1 seropositive contact.

Main Article

Page created: August 06, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external